Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, active-controlled, multiple-dose, open-label study to evaluate the safety, tolerability, and efficacy of the long-acting antibody-fused recombinant human growth hormone (GX-H9) in adult growth hormone deficiency (AGHD)

Next Previous
Search
Trial Profile

A randomized, active-controlled, multiple-dose, open-label study to evaluate the safety, tolerability, and efficacy of the long-acting antibody-fused recombinant human growth hormone (GX-H9) in adult growth hormone deficiency (AGHD)

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 17 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eftansomatropin (Primary) ; Somatropin
  • Indications Somatotropin deficiency
  • Focus Therapeutic Use
  • Sponsors Genexine

    • Most Recent Events

    • 01 Sep 2018 Results published in the European Journal of Endocrinology
    • 04 Apr 2017 Status changed from active, no longer recruiting to completed, according to the results presented at The 99th Annual Meeting of the Endocrine Society
    • 04 Apr 2017 Results of this study and interim results of another phase II study in patients with PGHD, presented at The 99th Annual Meeting of the Endocrine Society

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top